Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Aligos Therapeutics to Present Data from Chronic Hepatitis
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) --…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Chronic
Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory
--Response rate of 56% in patients treated monthly with high dose…
Dupixent® (dupilumab) Application for Treatment of Chronic
<!-- Name:DistributionId Value:8782894 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor…
The China study confirms a Phase 2a trial in Australia demonstrating ABP-671 significantly reduces serum uric acid levels and is well tolerated
JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical…
Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product,…
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the…
Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at…
ABP-671 effective at lowering serum uric acid, the cause of gout
JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced…
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled…
-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the treatment period --
DUBLIN--(BUSINESS…